Zenlabs Ethica Ltd (ZENLABS) — shareholding pattern, promoter holding, financials and share price
About Zenlabs Ethica Ltd (ZENLABS)
Zenlabs Ethica Ltd operates in the Diversified Commercial Services industry, within the Services sector. It trades on the NSE as ZENLABS and on the BSE under scrip code 530697. Its ISIN is INE546F01013.
Incorporated in 1993, Zenlabs Ethica Ltd deals in marketing and distribution of pharmaceutical products. [1]
Zenlabs Ethica Limited is a leading pharmaceutical contract marketing and trading company in India, known for its diverse range of branded drugs.
The company was launched in collaboration with Zenlabs Pharmaceutical Inc, Canada, and has a strong focus on quality and affordable drug distribution.
Listed peers in Diversified Commercial Services: ERP Soft Systems Ltd, Identical Brains Studios Ltd, Esaar (India) Ltd, Triliance Polymers Ltd, Madhya Pradesh Today Media Ltd, Vrundavan Plantation Ltd.
Valuation & Returns
10 Jul 2026At ₹34.85 a share on 10 Jul 2026, Zenlabs Ethica Ltd (ZENLABS) was valued at a price-to-earnings ratio of -11.7x against an industry P/E of 21.24x and a price-to-book of 2.18x on a book value of ₹16.01 per share as of Mar 2025. Solomo computes return on equity of -18.61% and return on capital employed of -4.32% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -11.7x
- Industry P/E
- 21.24x
- P/B
- 2.18x
- EPS (TTM)
- ₹-2.98
- Book value / share
- ₹16.01
- ROE
- -18.61%
- ROCE
- -4.32%
- ROA
- -4.78%
- Debt / equity
- 1.22x
- Dividend yield
- 0%
- EBITDA margin
- -0.21%
- 52-week range
- ₹16.5 – ₹39.99
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Zenlabs Ethica Ltd (ZENLABS) reported revenue of ₹46.92 crore, net profit of ₹-1.94 crore and earnings per share of ₹-2.98. That compares with revenue of ₹51.42 crore and net profit of ₹0.27 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹10.58 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 69.09 | 66.89 | 58.56 | 51.42 | 46.92 |
| Net profit (₹ cr) | 0.78 | 0.49 | 0.42 | 0.27 | -1.94 |
| EPS (₹) | 1.2 | 0.75 | 0.65 | 0.41 | -2.98 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 14.05% | -3.02% | -9.37% | -12.19% |
| Profit growth | 5.22% | - | -29.92% | -35.71% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.96% of Zenlabs Ethica Ltd (ZENLABS) (unchanged from the previous quarter). Market capitalisation was ₹23 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HITESH POPATLAL OSWAL 6.79%, HUF 4.39%, B S MALLIKARJUNA 2.14%, BHASAKARRAI KANYALAL BHATT 1.86%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.96% | - | - | - | 47.04% |
| Mar 2026 | 52.96% | - | - | - | 47.04% |
| Dec 2025 | 52.96% | - | - | - | 47.04% |
| Sep 2025 | 52.96% | - | - | - | 47.04% |
| Jun 2025 | 52.96% | - | - | - | 47.04% |
| Mar 2025 | 52.96% | - | - | - | 47.04% |
| Dec 2024 | 52.96% | - | - | - | 47.04% |
| Sep 2024 | 52.96% | - | - | - | 47.04% |